Table 1.
List of some recent clinical trials with mammalian target of rapamycin inhibitors
| Drug name(s) | Title of study | Trial status | References |
|---|---|---|---|
| Sirolimus | A pilot study evaluating the use of mTOR inhibitor sirolimus in children and young adults with desmoid-type fibromatosis | Phase I and II | [97] |
| Gemcitabine + rapamycin | Gemcitabine plus rapamycin versus gemcitabine to treat advanced soft tissue sarcoma | Phase I and II (completed) | [98] |
| Sirolimus | Pulsed oral sirolimus in autosomal dominant polycystic kidney disease—the Vienna rap study | Phase III | [99] |
| Everolimus | Controlled level everolimus in acute coronary syndromes | Phase I and II | [100] |
| Rapamycin | Prospective study of rapamycin for the treatment of SLE | Phase II | [101] |
| Everolimus | A phase II study of everolimus in patients with primary or relapsed chondrosarcomas | Phase II | [102] |
| Everolimus + lenalidomide | Everolimus and lenalidomide in treating patients with relapsed or refractory non-Hodgkin or Hodgkin lymphoma | Phase I and II | [103] |
| Everolimus + trastuzumab + vinorelbine | Daily everolimus in combination with trastuzumab and vinorelbine in HER2/Neu positive women with locally advanced or metastatic breast cancer | Phase III | [104] |
| Rapamycin | Neoadjuvant rapamycin in patients undergoing radical cystectomy | Phase 0 (completed) | [105] |
| Temsirolimus | Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Phase III | [106] |
| Temsirolimus + hydroxychloroquine | Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma | Phase I | [107] |
| Everolimus + lenalidomide | Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide | Phase I | [108] |
| Temsirolimus + irinotecan + temozolomide | Phase I trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children’s Oncology Group Study | Phase I and II | [109] |
HER human epidermal receptor, SLE systemic lupus erythematosus